Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gallium Ga-68 P15-041 is a radiopharmaceutical PET tracer designed for the high-sensitivity imaging of Carbonic Anhydrase IX (CAIX) expression. CAIX is a transmembrane enzyme that is significantly overexpressed in clear cell renal cell carcinoma (ccRCC) and various tumors associated with Von Hippel-Lindau (VHL) disease, such as hemangioblastomas and pancreatic neuroendocrine tumors, due to the stabilization of hypoxia-inducible factors (HIF). Developed by Ospedale San Raffaele, the tracer consists of a small-molecule CAIX inhibitor (P15-041) chelated with the positron-emitting radioisotope Gallium-68. This allows for non-invasive detection and monitoring of multi-organ lesions in VHL patients, where CAIX serves as a highly specific biomarker for VHL-deficient cells. The tracer is primarily utilized in Positron Emission Tomography/Computed Tomography (PET/CT) imaging to improve staging and management of VHL-related manifestations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on gallium Ga-68 P15-041.